Physician profile
Dennis Aumentado
NPI 1023039740
$70,070.87
in general payments reported to CMS, 2019-2025
74 companies · $6,720 in 2025
The $6,720 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $7,820 · 2021: $14K · 2022: $12K · 2023: $6,424 · 2024: $7,127 · 2025: $6,720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20K · Education: $297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19,974.29 |
| Education | $296.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $11,233.64 | 2021-2025 | Ubrelvy, Qulipta |
| Neurocrine Biosciences, INC. | $7,624.86 | 2019-2025 | Ingrezza, Ongentys |
| Sunovion Pharmaceuticals INC. | $6,126.17 | 2019-2020 | |
| Sk Life Science, INC. | $5,830.20 | 2020-2025 | Xcopri |
| Allergan, INC. | $5,413.85 | 2019-2021 | |
| Emd Serono, INC. | $3,161.32 | 2020-2025 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $2,428.99 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Ucb, INC. | $2,028.84 | 2019-2025 | Briviact, Fintepla, Rystiggo |
| Lundbeck LLC | $1,617.24 | 2019-2025 | Vyepti, Rexulti |
| Eisai INC. | $1,572.02 | 2019-2025 | |
| Pfizer INC. | $1,454.35 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $1,446.19 | 2019-2025 | Nuplazid, Daybue |
| Novartis Pharmaceuticals Corporation | $1,433.56 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $1,426.80 | 2019-2025 | Rytary, Lyvispah, Ongentys |
| Biogen, INC. | $1,410.87 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Aumentado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.